Breast cancer and cyclin D1 gene polymorphism in Turkish women

In Vivo

Volumn 23, Issue 5, 2009, Pages 767-772

  Yaylim Eraltan, Ilhan ^a   Ergen, Arzu ^a   Görmüş, Uzay ^a   Arikan, Soykan ^b   Küçücük, Seden ^a   Şahin, Orhan ^b   Yiǧit, Nilüfer ^a   Yildiz, Yemliha ^a   Isbir, Turgay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Istanbul Research and Teaching and Research Hospital   (Turkey)

Author keywords

Breast; Carcinoma; CCND1; Invasion; RFLP

Indexed keywords

CYCLIN D1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

EID: 70350053086     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
2. 1 to complete the cell cycle. Proc Natl Acad Sci USA 91: 8022-8026, 1994.
3. Zhou P, Jiang W, Weghorst CM and Weinstein IB: Overexpression of cyclin D enhances gene amplification. Cancer Res 56: 36-39, 1996. (Pubitemid 26011459)
4. Sutherland RL and Musgrove EA: Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4: 14-17, 2002. (Pubitemid 34097551)
5. Donnellan R and Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 51: 1-7, 1998.
6. Gillett C, Smith P, Gregory W, Richards M, Milis R, Peters G. and Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99, 1996. (Pubitemid 26167163)
7. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WDJ and Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11: 1005-1011, 1995.
8. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M and Saito I: Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 16: 1701-1712, 1998. (Pubitemid 28175051)
9. Weinstein IB, Begemann M, ZhouP, Han EK, Sgambato A, Doki Y, Arber N, Ciaparrone M and Yamamoto H: Disorders in cell circuitry associated with multistage cacinogenesis:exploitable targets for cancer prevention and therapy. Clin Cancer Res 5: 2696-2702, 1997. (Pubitemid 28133129)
10. Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G, Wu M, Wei L, He M, Zhang L and Wang S: Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 105: 281-284, 2003. (Pubitemid 36505334)
11. Yu CP, Yu JC, Sun CA, Tzao C, Ho JY and Yen AM: Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107: 95-102, 2008. (Pubitemid 350179583)
12. Howe D and Lynas C: The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 8: 563-569, 2001.
13. Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, Frazier ML, Spitz MR and Wei Q: Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case control study. Carcinogenesis 22: 1195-1199, 2001. (Pubitemid 32737335)
14. Kong S, Wei Q, Amos CI, Lynch PM, Levin , Zong J and Frazier ML: Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 93: 1106-1108, 2001. (Pubitemid 32717544)
15. Le Marchand L, Seifried A, Lum-Jones A, Donlon T and Wilkens LR: Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 290: 2843-2848, 2003. (Pubitemid 37509493)
16. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, Ogawa O and Kato T: Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103: 116-120, 2003. (Pubitemid 35424214)
17. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O and Kato T: Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23: 257-264, 2002. (Pubitemid 34224000)
18. Grieu F, Malaney S, Ward R, Joseph D and Iacopetta B: Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23: 4257-4259, 2003. (Pubitemid 37474930)
19. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Weitzer W, Leithner A and Samonigg H: The870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 82: 165-168, 2003.
20. Shu XO, Moore DB, Cai Q, Cheng J, Wen W, Pierce L, Cai H, Gao YT and Zheng W: Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14: 91-97, 2005. (Pubitemid 40165288)
21. Miller SA, Dykes DD and Polesky HS: Simples salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215-1219, 1988.
22. Lewis RC, Bostick RM, Xie D, Deng Z, Wargovich MJ , Fina MF, Roufail WM and Geisinger KR: Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 63: 8549-8553, 2003.
23. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817, 1994.
24. Weinstein IB: Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem (Suppl) 25: 23-28, 1996.
25. Lamb J, Ladha MH, McMahon C, Sutherland RL and Ewen ME: Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20: 8667-8675, 2000. (Pubitemid 32245900)
26. Zhang S, Caamano J, Cooper F, Guo X and Klein-Szanto AJP: Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 102: 695-698, 1994.
27. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M and Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994.
28. Arber N, Gammon MD, Hibshoosh H, Britton JA, Zhang Y, Schonberg JB, Roterdam H, Fabian I, Holt PR and Weinstein IB: Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in the adenocarcinomas of the stomach. Hum Pathol 30: 1087-1092, 1999. (Pubitemid 29427166)
29. Sutter T, Doi S, Carnevale KA, Arber N and Weinstein IB: Expressions of cyclins D1 and E in human colon adenocarcinomas. J Med 28: 285-301, 1997. (Pubitemid 28168519)
30. Han EKH, Rubin MA, Lim T, Arber N, Xing WQ and Weinstein IB: Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35: 95-101, 1998. (Pubitemid 28183291)
31. Sicinski P and Weinberg RA: A specific role for cyclin D1 in mammary gland development. J. Mammary Gland Biol Neoplasia 2: 335-342, 1997.
32. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL and Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1: 1257-1260, 1995.
33. Sutherland RL, Hamilton JA, Sweeney KJA, Watts CKW and Musgrove EA: Expression and regulation of cyclin genes in breast cancer. Acta Oncol 34: 651-656, 1995.
34. Ceschi M, Sun CL, Berg D Van Den, Koh WP, Yu MC and Probst-Hensch N: The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26(8): 1457-1464, 2005. (Pubitemid 41417890)
35. Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis IL, Blomqvist C, Nevanlinna H and Ozcelik H: Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8: 6, 2008. (Pubitemid 351757059)
36. Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, Guo X, Wang X and Shen H: CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 26: Sep [Epub ahead of print], 2008.
37. Kong S, Amos CI, Luthra R, Lynch PM, Levin B and Frazier ML: Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60: 249-252, 2000. (Pubitemid 30070744)
38. Dhar KK, Branigan K, Howells RE, Musgrove C, Jones PW, Strange RC, Fryer AA, Redman CW and Hoban PR: Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer 9: 342-347, 1999. (Pubitemid 29399370)
39. Comings DE and MacMurray JP: Molecular heterosis: a review. Mol Genet Metab 71: 19-31, 2000.
40. Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J, Jones PW, Strange RC, Fryer AA and Hoban PR: Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 4: 2411-2418, 1998. (Pubitemid 28477906)
41. Monteiro E, Varzim G, Pires AM, Teixeira M and Lopes C: Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposure. Cancer Detect Prev 28: 237-243, 2004.
42. Holley SL, Matthias C, Jahnke V, Fryer AA, Strange RC and Hoban PR: Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol 41: 156-160, 2005. (Pubitemid 40202881)
43. Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, Lopes C and Medeiros R: Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 160: 49-54, 2005. (Pubitemid 40798136)
44. Fleming FJ, Kavanagh D, Crotty TB, Quinn CM, McDermott EW, O'Higgins N and Hill ADK: Factors affecting metastasis to non-sentinel lymph nodes in breast cancer. J Clin Pathol 57(1): 73-76, 2004. (Pubitemid 38091315)
45. Catarino RJ, Breda E, Coelho V, Pinto D, Sousa H, Lopes C and Medeiros R: Association of the A870G cyclin D1 gene polymorphism with genetic susceptibility to nasopharyngeal carcinoma. Head Neck 28(7): 603-608, 2006. (Pubitemid 44025108)